ClinicalTrials.gg
CompletedNCT00558467Updated May 16, 2014Results posted

Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria

A Phase 2 interventional study of pramipexole immediate release (IR) and Placebo in Tourette Syndrome, sponsored by Boehringer Ingelheim. Completed at 16 sites in 2 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2014-05-16.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.

Enrollment
36th of 105
63 · median 33
Started
2008
with 3 others
Phase 2
26 of 139
4 open now
Registered
27th of 139
by date

Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 36th largest by enrollment of the 105 interventional ones that give a count, is one of 4 that started in 2008, is one of 26 in phase 2, and was the 27th registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Tourette Syndrome with a site in United States, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole versus placebo for 6 weeks in children (age 6-17) diagnosed with Tourette Disorder according to DSM IV criteria. The primary efficacy measure will be the Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS) at 6 weeks.

03

Conditions studied

  • Tourette Syndrome

Browse trials for

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male of female patients 6-17 yrs.
  • Written .
  • Diagnosed with Tourette's Disorder with a > or equal to 22 on the Total Tic Score at baseline.
  • Diagnosed with Tourette's Disorder when administering the Diagnostic Interview Schedule for Children.
  • Having at least 1 tic/day.
  • Women of childbearing age must have a negative serum pregnancy test at screening and must use a medically accepted method.
  • Either a newly diagnosed patient or a patient diagnosed with Tourette's Disorder who can safely discontinue treatment.
  • Having a body weight of > or equal to 20 kg (44 lbs).

Exclusion criteria

Exclusion Criteria:

  • Any women of childbearing age having a positive serum pregnancy test at screening.
  • Patients who have renal disease or serum creatinine greater than 1.0 mg/dL at screening.
  • Lab results at screening: below lower limit of normal which is determined to be clinically significant; Thyroid Stimulating Hormone (TSH), triiodothyronine (T3) or thyroxine (T4) clinically significant; clinically significant abnormalities in labs.
  • Other clinically significant metabolic-endocrine, hematological, gastrointestinal disease, pulmonary disease which would preclude the patient from participating in this study.
  • History of Schizophrenia or any psychotic disorder, history of mental disorders or any present Axis I psychiatric disorder according to Diagnostic and Statistic Manual of Mental Disorders Fourth Edition () requiring any medical therapy except for patients with a diagnosis of attention deficit hyperactivity disorder (ADHD) or obsessive-compulsive disorder (OCD) who are not on therapy.
  • History of/or clinical signs of epilepsy or seizures other than fever related seizures in early childhood.
  • History of/or clinical signs of any malignant neoplasm.
  • Allergic response to pramipexole.
  • Had previous treatment with dopamine agonists other than pramipexole within 14 days prior to baseline visit.
  • Had any other medical treatment for Tourette's Disorder besides the study medication within 28 days prior to baseline visit.
  • Had withdrawal symptoms of any medication at screening or at the baseline visit.
  • Having a Kaufman Brief Intelligence Test (KBIT IQ) score \<70 at screening.
  • Having a children's Yale-Brown obsessive-compulsive scale (CY-BOCS) score of >15 at baseline.
  • Patients who meet criteria for Restless Legs Syndrome and or Periodic Limb Movement disorder.
  • Patients with severe asthma.
  • Patients that have initiated psychotherapy for Tourette's Disorder, OCD or ADHD within 3 mths of starting the trial.
  • Patients receiving psychological, cognitive and/or behavioral treatments greater than 3 mths prior to start of trial for Tourette's Disorder, OCD, and/or ADHD who will have changes in treatment plan.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Other
    Pramipexole

    Drug: pramipexole immediate release (IR)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Drugpramipexole immediate release (IR)
  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale

    Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50. Analysis was adjusted for baseline total tic score and age as linear covariates.

    Time frame: baseline 6 weeks

Secondary outcomes

  1. Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 1

    Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50

    Time frame: baseline 1 week

  2. Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 2

    Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50

    Time frame: baseline and 2 weeks

  3. Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 3

    Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50

    Time frame: baseline and 3 weeks

  4. Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 4

    Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50

    Time frame: baseline and 4 weeks

  5. Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 6

    Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)

    Time frame: baseline and 6 weeks

  6. Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 1

    Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)

    Time frame: baseline 1 week

  7. Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 2

    Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)

    Time frame: baseline and 2 weeks

  8. Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 3

    Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)

    Time frame: baseline and 3 weeks

  9. Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 4

    Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)

    Time frame: baseline 4 weeks

  10. Clinical Global Impressions - Improvement at 1 Week

    Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.

    Time frame: baseline and Week 1

  11. Clinical Global Impressions - Improvement at Week 2

    Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.

    Time frame: baseline and Week 2

  12. Clinical Global Impressions - Improvement at Week 3

    Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.

    Time frame: baseline and Week 3

  13. Clinical Global Impressions - Improvement at Week 4

    Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.

    Time frame: baseline and Week 4

  14. Clinical Global Impressions - Improvement at Week 6

    Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.

    Time frame: baseline and Week 6

  15. Clinical Global Impressions - Severity of Illness at Week 1

    Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.

    Time frame: baseline and Week 1

  16. Clinical Global Impressions - Severity of Illness at Week 2

    Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.

    Time frame: baseline and Week 2

  17. Clinical Global Impressions - Severity of Illness at Week 3

    Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.

    Time frame: baseline and Week 3

  18. Clinical Global Impressions - Severity of Illness at Week 4

    Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.

    Time frame: baseline and Week 4

  19. Clinical Global Impressions - Severity of Illness at Week 6

    Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.

    Time frame: baseline and Week 6

  20. Patient Global Impression at Week 1

    Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

    Time frame: baseline and Week 1

  21. Patient Global Impression at Week 2

    Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

    Time frame: baseline and Week 2

  22. Patient Global Impression at Week 3

    Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

    Time frame: baseline and Week 3

  23. Patient Global Impression at Week 4

    Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

    Time frame: baseline and Week 4

  24. Patient Global Impression at Week 6

    Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

    Time frame: baseline and Week 6

  25. Clinically Significant Abnormalities in Vital Signs (Orthostatic Reaction and Pulse Rate), and Serum Chemistry.

    Time frame: baseline and Week 6

07

Results

Posted Oct 20, 2010

Participant flow

Participant flow — Overall Study
MilestonePlaceboPramipexole
Started2043
Completed1939
Not completed14
Withdrew: Adverse event12
Withdrew: Lack of efficacy01
Withdrew: Patient moving out of state01

Outcome measures

PrimaryMean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale

Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50. Analysis was adjusted for baseline total tic score and age as linear covariates.

Time frame:
baseline 6 weeks
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale
score on a scalePlaceboPramipexole
Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale-7.17 ± 2.02-7.16 ± 1.38
Statistical analysis
  • Placebo vs Pramipexole · ANCOVA · p = 0.996 · Least squares mean difference: 0.01 · 95% CI -4.95 to 4.97
SecondaryMean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 1

Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50

Time frame:
baseline 1 week
Reported as:
Mean · score on a scale
Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 1
score on a scalePlaceboPramipexole
Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 1-3.7 ± 4.1-4.1 ± 5.4
Statistical analysis
  • Placebo vs Pramipexole · Repeated Measures · Least square means difference: -3.94 · 95% CI -5.81 to -2.08
SecondaryMean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 2

Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50

Time frame:
baseline and 2 weeks
Reported as:
Mean · score on a scale
Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 2
score on a scalePlaceboPramipexole
Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 2-5.3 ± 7.9-5 ± 7.4
Statistical analysis
  • Placebo vs Pramipexole · Repeated measures · Least square means difference: -5.30 · 95% CI -7.21 to -3.39
SecondaryMean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 3

Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50

Time frame:
baseline and 3 weeks
Reported as:
Mean · score on a scale
Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 3
score on a scalePlaceboPramipexole
Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 3-6.2 ± 6.3-5.4 ± 6.3
SecondaryMean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 4

Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50

Time frame:
baseline and 4 weeks
Reported as:
Mean · score on a scale
Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 4
score on a scalePlaceboPramipexole
Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 4-6 ± 7.9-6.4 ± 7.3
Statistical analysis
  • Placebo vs Pramipexole · Repeated measures · Least square means difference: -5.97 · 95% CI -7.88 to -4.06
SecondaryMean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 6

Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)

Time frame:
baseline and 6 weeks
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 6
score on a scalePlaceboPramipexole
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 6-15.43 ± 4.44-15.58 ± 3.03
Statistical analysis
  • Placebo vs Pramipexole · ANCOVA · p = 0.9780 · Least squares mean differnce: -0.15 · 95% CI -11.05 to 10.75
SecondaryMean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 1

Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)

Time frame:
baseline 1 week
Reported as:
Mean · score on a scale
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 1
score on a scalePlaceboPramipexole
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 1-6.2 ± 13.3-8.8 ± 11.1
SecondaryMean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 2

Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)

Time frame:
baseline and 2 weeks
Reported as:
Mean · score on a scale
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 2
score on a scalePlaceboPramipexole
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 2-9.5 ± 16.1-10.6 ± 17.5
SecondaryMean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 3

Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)

Time frame:
baseline and 3 weeks
Reported as:
Mean · score on a scale
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 3
score on a scalePlaceboPramipexole
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 3-14.1 ± 17.2-12.2 ± 15.7
SecondaryMean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 4

Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)

Time frame:
baseline 4 weeks
Reported as:
Mean · score on a scale
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 4
score on a scalePlaceboPramipexole
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 4-15.5 ± 18.2-13.9 ± 15.7
SecondaryClinical Global Impressions - Improvement at 1 Week

Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.

Time frame:
baseline and Week 1
Reported as:
Number · Number of Patients
Clinical Global Impressions - Improvement at 1 Week
Number of PatientsPlaceboPramipexole
Responder05
Not Responder2037
Statistical analysis
  • Placebo vs Pramipexole · Cochran-Mantel-Haenszel · p = 0.1052
SecondaryClinical Global Impressions - Improvement at Week 2

Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.

Time frame:
baseline and Week 2
Reported as:
Number · Number of Patients
Clinical Global Impressions - Improvement at Week 2
Number of PatientsPlaceboPramipexole
Responder16
Not Responder1936
Statistical analysis
  • Placebo vs Pramipexole · Cochran-Mantel-Haenszel · p = 0.2274
SecondaryClinical Global Impressions - Improvement at Week 3

Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.

Time frame:
baseline and Week 3
Reported as:
Number · Number of Patients
Clinical Global Impressions - Improvement at Week 3
Number of PatientsPlaceboPramipexole
Responder25
Not Responder1837
Statistical analysis
  • Placebo vs Pramipexole · Cochran-Mantel-Haenszel · p = 0.7691
SecondaryClinical Global Impressions - Improvement at Week 4

Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.

Time frame:
baseline and Week 4
Reported as:
Number · Number of Patients
Clinical Global Impressions - Improvement at Week 4
Number of PatientsPlaceboPramipexole
Responder76
Not Responder1336
Statistical analysis
  • Placebo vs Pramipexole · Cochran-Mantel-Haenszel · p = 0.0674
SecondaryClinical Global Impressions - Improvement at Week 6

Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.

Time frame:
baseline and Week 6
Reported as:
Number · Number of Patients
Clinical Global Impressions - Improvement at Week 6
Number of PatientsPlaceboPramipexole
Responder711
Not Responder1331
Statistical analysis
  • Placebo vs Pramipexole · Cochran-Mantel-Haenszel · p = 0.4944
SecondaryClinical Global Impressions - Severity of Illness at Week 1

Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.

Time frame:
baseline and Week 1
Reported as:
Number · Number of Patients
Clinical Global Impressions - Severity of Illness at Week 1
Number of PatientsPlaceboPramipexole
Improved04
Unchanged2038
Worsened00
Statistical analysis
  • Placebo vs Pramipexole · Cochran-Mantel-Haenszel · p = 0.162
SecondaryClinical Global Impressions - Severity of Illness at Week 2

Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.

Time frame:
baseline and Week 2
Reported as:
Number · Number of Patients
Clinical Global Impressions - Severity of Illness at Week 2
Number of PatientsPlaceboPramipexole
Improved14
Unchanged1937
Worsened01
Statistical analysis
  • Placebo vs Pramipexole · Cochran-Mantel-Haenszel · p = 0.6375
SecondaryClinical Global Impressions - Severity of Illness at Week 3

Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.

Time frame:
baseline and Week 3
Reported as:
Number · Number of Patients
Clinical Global Impressions - Severity of Illness at Week 3
Number of PatientsPlaceboPramipexole
Improved34
Unchanged1737
Worsened01
Statistical analysis
  • Placebo vs Pramipexole · Cochran-Mantel-Haenszel · p = 0.6625
SecondaryClinical Global Impressions - Severity of Illness at Week 4

Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.

Time frame:
baseline and Week 4
Reported as:
Number · Number of Patients
Clinical Global Impressions - Severity of Illness at Week 4
Number of PatientsPlaceboPramipexole
Improved44
Unchanged1638
Worsened00
Statistical analysis
  • Placebo vs Pramipexole · Cochran-Mantel-Haenszel · p = 0.2664
SecondaryClinical Global Impressions - Severity of Illness at Week 6

Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.

Time frame:
baseline and Week 6
Reported as:
Number · Number of Patients
Clinical Global Impressions - Severity of Illness at Week 6
Number of PatientsPlaceboPramipexole
Improved410
Unchanged1632
Worsened00
Statistical analysis
  • Placebo vs Pramipexole · Cochran-Mantel-Haenszel · p = 0.7302
SecondaryPatient Global Impression at Week 1

Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

Time frame:
baseline and Week 1
Reported as:
Number · Number of Patients
Patient Global Impression at Week 1
Number of PatientsPlaceboPramipexole
Responder47
Not Responder1635
Statistical analysis
  • Placebo vs Pramipexole · Cochran-Mantel-Haenszel · p = 0.7723
SecondaryPatient Global Impression at Week 2

Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

Time frame:
baseline and Week 2
Reported as:
Number · Number of Patients
Patient Global Impression at Week 2
Number of PatientsPlaceboPramipexole
Responder69
Not Responder1433
Statistical analysis
  • Placebo vs Pramipexole · Cochran-Mantel-Haenszel · p = 0.4852
SecondaryPatient Global Impression at Week 3

Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

Time frame:
baseline and Week 3
Reported as:
Number · Number of Patients
Patient Global Impression at Week 3
Number of PatientsPlaceboPramipexole
Responder57
Not Responder1535
Statistical analysis
  • Placebo vs Pramipexole · Cochran-Mantel-Haenszel · p = 0.4607
SecondaryPatient Global Impression at Week 4

Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

Time frame:
baseline and Week 4
Reported as:
Number · Number of Patients
Patient Global Impression at Week 4
Number of PatientsPlaceboPramipexole
Responder47
Not Responder1635
Statistical analysis
  • Placebo vs Pramipexole · Cochran-Mantel-Haenszel · p = 0.7723
SecondaryPatient Global Impression at Week 6

Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

Time frame:
baseline and Week 6
Reported as:
Number · Number of Patients
Patient Global Impression at Week 6
Number of PatientsPlaceboPramipexole
Responder612
Not Responder1430
Statistical analysis
  • Placebo vs Pramipexole · Cochran-Mantel-Haenszel · p = 0.9389
SecondaryClinically Significant Abnormalities in Vital Signs (Orthostatic Reaction and Pulse Rate), and Serum Chemistry.
Time frame:
baseline and Week 6
Reported as:
Number · participants
Clinically Significant Abnormalities in Vital Signs (Orthostatic Reaction and Pulse Rate), and Serum Chemistry.
participantsPlaceboPramipexole
Phosphate - increase25
Bilirubin, total - increase01
Tachycardia01
Orthostatic hypotension14

Adverse events

Collected over All events with an onset after the first dose of study medication and up to a period of 48 hours after the last dose of study medication were assigned to the treatment period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/20 (5%)13/20 (65%)
Pramipexole—0/43 (0%)25/43 (58.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboPramipexole
Gastroenteritis viralInfections and infestations1/200/43
DehydrationMetabolism and nutrition disorders1/200/43
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPlaceboPramipexole
HeadacheNervous system disorders5/2012/43
NauseaGastrointestinal disorders2/208/43
DizzinessNervous system disorders3/203/43
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/203/43
VomitingGastrointestinal disorders0/205/43
DiarrhoeaGastrointestinal disorders2/203/43
FatigueGeneral disorders2/204/43
PyrexiaGeneral disorders2/202/43
NasopharyngitisInfections and infestations2/202/43
TicPsychiatric disorders2/201/43

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboPramipexoleTotal
Mean11.1 ± 3.212.2 ± 2.411.8 ± 2.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPramipexoleTotal
Female2810
Male183553
Attention Deficit Hyperactive Disorder
Attention Deficit Hyperactive Disorder(Number of Patients)PlaceboPramipexoleTotal
Intermediate369
Negative92231
Positive81523
Duration of Tourettes syndrome
Duration of Tourettes syndrome(participants)PlaceboPramipexoleTotal
1-5 years101929
Less than 1 years61218
More than 5 years41216
Ethnicity, Customized
Ethnicity, Customized(Number of Patients)PlaceboPramipexoleTotal
Hispanic/Latino257
Not Hispanic/Latino183856
Obsessive Compulsive Disorder
Obsessive Compulsive Disorder(participants)PlaceboPramipexoleTotal
Intermediate134
Negative163753
Positive336
Race, Customized
Race, Customized(participants)PlaceboPramipexoleTotal
Black/African American246
White183957
Body Mass Index
Body Mass Index(kilograms/(meters squared))PlaceboPramipexoleTotal
Mean20.085 ± 5.32422.575 ± 5.65621.784 ± 5.632

2 further baseline measures are reported on the registry.

08

Study locations

16 sites
  • 248.644.0026 Boehringer Ingelheim Investigational Site
    Bradenton, Florida, United States
  • 248.644.0025 Boehringer Ingelheim Investigational Site
    Tampa, Florida, United States
  • 248.644.0006 Boehringer Ingelheim Investigational Site
    Columbus, Georgia, United States
  • 248.644.0012 Boehringer Ingelheim Investigational Site
    Chicago, Illinois, United States
  • 248.644.0005 Boehringer Ingelheim Investigational Site
    Cambridge, Massachusetts, United States
  • 248.644.0003 Boehringer Ingelheim Investigational Site
    Manhasset, New York, United States
  • 248.644.0009 Boehringer Ingelheim Investigational Site
    New York, New York, United States
  • 248.644.0018 Boehringer Ingelheim Investigational Site
    New York, New York, United States
  • 248.644.0013 Boehringer Ingelheim Investigational Site
    Orangeburg, New York, United States
  • 248.644.0029 Boehringer Ingelheim Investigational Site
    Oklahoma City, Oklahoma, United States
  • 248.644.0010 Boehringer Ingelheim Investigational Site
    Providence, Rhode Island, United States
  • 248.644.0030 Boehringer Ingelheim Investigational Site
    Memphis, Tennessee, United States
  • 248.644.0008 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 248.644.0023 Boehringer Ingelheim Investigational Site
    Norfolk, Virginia, United States
  • 248.644.49001 Boehringer Ingelheim Investigational Site
    Hannover, Germany
  • 248.644.49004 Boehringer Ingelheim Investigational Site
    Ulm, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008 and a primary completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2010, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2007
First posted
Nov 15, 2007
Start
Jan 2008
Primary completionActual
Jun 2009
Results first posted
Oct 20, 2010
Last update
May 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00558467
Responsible party
Sponsor
First posted
Nov 15, 2007
Start date
Jan 2008
Primary completion
Jun 2009
Results posted
Oct 20, 2010
Last update
May 16, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion